Phathom Pharmaceuticals Announces $130 Million Public Offering
TipRanks (Thu, 8-Jan 4:36 PM ET)
TipRanks (Thu, 8-Jan 10:01 AM ET)
Market Chameleon (Thu, 8-Jan 3:37 AM ET)
Stock Market Today: S&P 500, Dow Jones Futures Decline — AZZ, Northrop Grumman, Immuneering In Focus
Benzinga (Thu, 8-Jan 5:17 AM ET)
Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Benzinga (Thu, 8-Jan 4:25 AM ET)
Phathom slumps 12%; prices $130M stock at $16 per share
Seeking Alpha News (Thu, 8-Jan 1:40 AM ET)
Phantom slumps 12%; prices $130M stock at $16 per share
Seeking Alpha News (Thu, 8-Jan 1:40 AM ET)
Globe Newswire (Wed, 7-Jan 10:33 PM ET)
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Globe Newswire (Wed, 7-Jan 4:05 PM ET)
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Wed, 7-Jan 4:01 PM ET)
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Phathom Pharmaceuticals trades on the NASDAQ stock market under the symbol PHAT.
As of January 13, 2026, PHAT stock price climbed to $15.42 with 841,516 million shares trading.
PHAT has a beta of 2.17, meaning it tends to be more sensitive to market movements. PHAT has a correlation of 0.10 to the broad based SPY ETF.
PHAT has a market cap of $1.20 billion. This is considered a Small Cap stock.
Last quarter Phathom Pharmaceuticals reported $50 million in Revenue and -$.15 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.26.
In the last 3 years, PHAT traded as high as $19.71 and as low as $2.21.
The top ETF exchange traded funds that PHAT belongs to (by Net Assets): VTI, IWM, VXF, DWAS, IBB.
PHAT has outperformed the market in the last year with a return of +122.2%, while the SPY ETF gained +20.5%. In the last 3 month period, PHAT beat the market returning +30.5%, while SPY returned +6.3%. However, in the most recent 2 weeks PHAT has underperformed the stock market by returning -10.5%, while SPY returned +0.6%.
PHAT support price is $13.68 and resistance is $15.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PHAT shares will trade within this expected range on the day.